UNSPSC 51144113: Clobenzorex

This classification denotes an anorexiant with the molecular formula C16H18ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4A5352XI2A, chemically known as benzeneethanamine, n-((2-chlorophenyl)methyl)-alpha-methyl-, (+)- but more generally known as clobenzorex, which bears US NIH Compound Identifier 71675. European Medicines Agency schedules Clobenzorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06676MIG.

UNSPSC 51144113 Clobenzorex, a Commodity code, nominally refers to a specific pharmaceutical stimulant; however, the single recent state and local opportunity tagged under this code does not align with the code's stated scope. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking to procure naloxone (an opioid-reversal medication) and safe drug deactivation systems—products unrelated to clobenzorex. This mismatch suggests either a miscoding error in the county's procurement system or a data quality issue in the taxonomy application. The code shows minimal verifiable recent activity in state and local procurement aligned with its nominal pharmaceutical scope.

The Seminole County opportunity, due July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option and is potentially funded through FEMA, requiring compliance with federal environmental regulations. Vendors must meet standard state and local requirements including drug-free workplace certification, E-Verify compliance, and specified insurance coverage; the solicitation notes no explicit set-asides for disadvantaged enterprises. Given the single recent posting under this code and its product mismatch, pursuit under UNSPSC 51144113 appears impractical—business development efforts would be better directed toward the appropriate pharmaceutical or public health commodity codes under which naloxone and harm-reduction supplies are typically classified.